Therapeutic agents for neurodegenerative diseases
The present disclosure provides for treating neurodegenerative diseases comprising administering leucine, acetyl-leucine or a pharmaceutically acceptable salt thereof.
1. A method of treating restless legs syndrome (RLS) in a subject who has a neurodegenerative disease comprising:
administering to the subject a therapeutically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the neurodegenerative disease is parkinsonism.
3. The method of claim 1 , wherein the neurodegenerative disease is a Motor Neuron Disease.
4. The method of claim 1 , wherein the neurodegenerative disease is Parkinson's Disease.
5. The method of claim 1 , wherein the neurodegenerative disease is associated with dopaminergic system dysfunction.
6. The method of claim 1 , wherein the leucine is DL-leucine.
7. The method of claim 1 , wherein the acetyl-leucine is acetyl-DL-leucine.
8. The method of claim 1 , wherein the leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer.
9. The method of claim 1 , wherein the acetyl-leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer.
10. The method of claim 1 , wherein the therapeutically effective amount of acetyl-leucine is chosen from about 1 g to about 15 g per day, about 1 g to about 10 g per day, about 1.5 g to about 7 g per day, about 4 g to about 6 g per day, and about 4 g to about 5 g per day.
11. The method of claim 1 , wherein the treatment decreases the subject's International Restless Leg Syndrome Study Group Rating Scale (“IRLS”) compared to a baseline.
12. The method of claim 11 , wherein the IRLS is reduced compared to the baseline by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%.
13. The method of claim 1 , wherein the administering step is for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years.
14. A method of treating restless legs syndrome (RLS) in a subject in need thereof, wherein the RLS is a symptom of a neurodegenerative disease, the method comprising administering to the subject a therapeutically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof.
15. The method of claim 14 , wherein the leucine is DL-leucine.
16. The method of claim 14 , wherein the acetyl-leucine is acetyl-DL-leucine.
17. The method of claim 14 , wherein the leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer.
18. The method of claim 14 , wherein the acetyl-leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer.
19. The method of claim 14 , wherein the therapeutically effective amount of acetyl-leucine is chosen from about 1 g to about 15 g per day, about 1 g to about 10 g per day, about 1.5 g to about 7 g per day, about 4 g to about 6 g per day, and about 4 g to about 5 g per day.
20. The method of claim 14 , wherein the treatment decreases the subject's International Restless Leg Syndrome Study Group Rating Scale (“IRLS”) compared to a baseline.
21. The method of claim 20 , wherein the IRLS is reduced compared to the baseline by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%.
22. The method of claim 14 , wherein the administering step is for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years.